Transcriptional repression of tissue inhibitor of metalloproteinase-3 by Epstein-Barr virus latent membrane protein 1 enhances invasiveness of nasopharyngeal carcinoma cells

Oral Oncology

Volumn 44, Issue 9, 2008, Pages 891-897

  Chang, Shu Hui ^a   Chang, Hui Chiu ^b,c   Hung, Wen Chun ^c  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

Epstein Barr virus; Latent membrane protein 1; Nasopharyngeal carcinoma; p38 Kinase; Tissue inhibitor of metalloproteinase 3

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; LATENT MEMBRANE PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; VIRUS PROTEIN;

ARTICLE; CANCER INVASION; CARCINOMA CELL; CELL MIGRATION; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DOWN REGULATION; DRUG EFFECT; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CARCINOMA, SQUAMOUS CELL; DOWN-REGULATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; NASOPHARYNGEAL NEOPLASMS; NEOPLASM INVASIVENESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROMOTER REGIONS, GENETIC; PYRIDINES; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; VIRAL MATRIX PROTEINS;

EID: 50049104766     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2007.11.005     Document Type: Article

References (30)

1. Young L.S., and Murray P.G. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 22 (2003) 5108-5121
2. Klein E., Kis L.L., and Klein G. Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions. Oncogene 26 (2007) 1297-1305
3. Suarez F., Lortholary O., Hermine O., and Lecuit M. Infection- associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood 107 (2006) 3034-3044
4. Hitt M.M., Allday M.J., Hara T., Karran L., Jones M.D., Busson P., et al. EBV gene expression in an NPC-related tumour. EMBO J 8 (1989) 2639-2651
5. Chan A.T., Teo P.M., and Huang D.P. Pathogenesis and treatment of nasopharyngeal carcinoma. Semin Oncol 31 (2004) 794-801
6. Longnecker R., Druker B., Roberts T.M., and Kieff E. An Epstein-Barr virus protein associated with cell growth transformation interacts with a tyrosine kinase. J Virol 65 (1991) 3681-3692
7. Hu L.F., Chen F., Zhen Q.F., Zhang Y.W., Luo Y., Zheng X., et al. Differences in the growth pattern and clinical course of EBV-LMP1 expressing and non-expressing nasopharyngeal carcinomas. Eur J Cancer 31A (1995) 658-660
8. Horikawa T., Yoshizaki T., Sheen T.S., Lee S.Y., and Furukawa M. Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer 89 (2000) 715-723
9. Murono S., Inoue H., Tanabe T., Joab I., Yoshizaki T., Furukawa M., et al. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci USA 98 (2001) 6905-6910
10. Hojilla C.V., Mohammed F.F., and Khokha R. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Brit J Cancer 89 (2003) 1817-1821
11. Vihinen P., Ala-aho R., and Kähäri V.M. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 5 (2005) 203-220
12. Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont ES. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol. 50, 87-100.
13. Murono S., Yoshizaki T., Sato H., Takeshita H., Furukawa M., and Pagano J.S. Aspirin inhibits tumor cell invasiveness induced by Epstein-Barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression. Cancer Res 60 (2000) 2555-2561
14. Liu L.T., Peng J.P., Chang H.C., and Hung W.C. RECK is a target of Epstein-Barr virus latent membrane protein 1. Oncogene 22 (2003) 8263-8270
15. Noda M., Kitayama H., Matsuzaki T., Sugimoto Y., Okayama H., Bassin R.H., et al. Proc Natl Acad Sci USA 86 (1989) 162-166
16. Takahashi C., Sheng Z., Horan T.P., Kitayama H., Maki M., Hitomi K., et al. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci USA 95 (1998) 13221-13226
17. Lin C.T., Wong C.I., Chan W.Y., Tzung K.W., Ho J.K., Hsu M.M., et al. Establishment and characterization of two nasopharyngeal carcinoma cell lines. Lab Invest. 62 (1990) 713-724
18. Liu L.T., Chang H.C., Chiang L.C., and Hung W.C. Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res 63 (2003) 3069-3072
19. Tsao S.W., Tramoutanis G., Dawson C.W., Lo A.K.F., and Huang D.P. The significance of LMP1 expression in nasopharyngeal carcinoma. Semin Cancer Biol 12 (2002) 473-487
20. Li H.P., and Chang Y.S. Epstein-Barr virus latent membrane protein 1: structure and functions. J Biomed Sci 10 (2003) 490-504
21. Eliopoulos A.G., Gallagher N.J., Blake S.M., Dawson C.X., and Young L.S. Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem 274 (1999) 16085-16096
22. Vockerodt M., Haier B., Buttgereit P., Tesch H., and Kube D. The Epstein-Barr latent membrane protein 1 induces interleukin 10 in Burkitt's lymphoma cells but not in Hodgkin's cells involving the p38/SAPK2 pathway. Virology 280 (2001) 183-198
23. Lo A.K.F., Lo K.W., Tsao S.W., Wong H.L., Hui J.W.Y., To K.F., et al. Epstein-Barr virus infection alters cellular signal cascades in human nasopharyngeal epithelial cells. Neoplasia 8 (2006) 173-180
24. Lee D.C.W., Chua D.T.T., Wei W.I., Sham J.S.T., and Lau A.S.Y. Induction of matrix metalloproteinases by Epstein-Barr virus latent membrane protein 1 isolated from nasopharyngeal carcinoma. Biomed Pharmacother 61 (2007) 520-526
25. Weber B.H., Vogt G., Pruett R.C., Stöhr H., and Felbor U. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy. Nat Genet 8 (1994) 352-356
26. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385 (1997) 729-733
27. Baker A.H., George S.J., Zaltsman A.B., Murphy G., and Newby A.C. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Brit J Cancer 79 (1999) 1347-1355
28. Anand-Apte B., Pepper M.S., Voest E., Montesano R., Olsen B., Murphy G., et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest Ophthalmol Vis Sci 38 (1997) 817-823
29. Chang M.S., Uozaki H., Chong J.M., Ushiku T., Sakuma K., Ishikawa S., et al. CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus. Clin Cancer Res 12 (2006) 2995-3002
30. Zhang Y., Ohyashiki J.H., Takaku T., Shimizu N., and Ohyashiki K. Transcriptional profiling of Epstein-Barr virus (EBV) genes and host cellular genes in nasal NK/T-cell lymphoma and chronic active EBV infection. Brit J Cancer 94 (2006) 599-608